MI3 Market Alert: Next generation pharmaceutical products for unmet medical needs

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on IntelGenx Technologies Corp.

  • IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.
  • IntelGennx is currently conducting scale-up activities for cannabis-infused oral film product for an anticipated commercial launch. With the recent Cannabis Act amendments authorizing the sale of new classes of cannabis products, including oral films, we are well-positioned participate in the expanded cannabis market just as new product formats come online.
  • Rebounding since 70 cents … next target $0.93 …Echelon Wealth Partners rate IGX at $1.60
  • Support: S2; $0.70    S1; $0.78   Resistance:   R1; $ 0.89    R2; $0.93

About IntelGenx:

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.




MI3 Market Alert: A leading oral drug delivery company with proprietary VersaFilm® technology

Mario Drolet President of MI3 Communications Financières Inc. (MI3) released a technical note at market open today on IntelGenx Corp.  (TSXV: IGX | OTCQX: IGXT) for exclusive distribution on InvestorIntel. In this note, MI3 highlighted the following points on IntelGenx Corp.

  • IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm® technology platform.
  • IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. Established for the VersaFilm® technology platform, IntelGenx’s state-of-the-art manufacturing facility supports lab-scale-to-pilot and commercial-scale production, offering full-service capabilities to our clients.
  • RSI AT 77. MACD … bullish … recent spike can indicate a catalyst is imminent!!!
  • Daily volume on the rise … IGX traded over 680 000 shares since Sept 2
  • Support: S2; $ 0.75    S1; $ 0.85   Resistance:   R1; $ 0.94     R2; $ 1.00

About IntelGenx:

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, VetaFilm™ and transdermal, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offer significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This MI3 Technical Note produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this note.




InvestorIntel Interviews Dr. Zerbe of IntelGenx on Cialis deal

In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX |OTCQX: IGXT), discusses the recent deal with Eli Lilly to manufacture Tadalafil (also known as Cialis®) as a pharmaceutical oral film, using IntelGenx’s VersaFilm™ technology. IntelGenx’s tadalafil oral film offers an improved discrete dosage form that does not require water intake. Dr. Zerbe states that this deal is significant because moving forward potential partner licensees will not face any litigation after completing a deal with IntelGenx, making the launch and commercialization of a VersaFilm™  partnered product extremely easy…to access the complete interview, click here

Disclaimer: IntelGenx Technologies Corp. is an advertorial member of InvestorIntel Corp.

 




IntelGenx CEO speaks to the potential impact of Montelukast on Alzheimers

In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) discusses the invention of their pharmaceutical oral film, VersaFilm™ and its drug delivery technology advantage. Dr. Zerbe says that their “objective is to improve the efficacy of a drug and its availability in the body.” Utilizing the VersaFilm™ technology, he comments upon IntelGenx’s experimentation with the drug commonly used to treat asthma — Montelukast.

He comments: “We discovered Montelukast as a great asset management opportunity. Montelukast has been approved for many years as a treatment for asthma. There is very, very impressive research that was recently published indicating that it could be a very effective Alzheimer’s treatment. That is very important for the patient because today there is no treatment available that can reverse the effects of the Alzheimer’s disease, but Montelukast has the potential to do that.” — To access the full interview, click here

Disclaimer:  IntelGenx Technologies Corp. is an advertorial member of InvestorIntel Corp.